Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edap Tms S.A. (EDAP)
NASDAQ:EDAP
Holding EDAP?
Track your performance easily
EDAP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.27 - $8.50
Previous Close$2.47
Volume94.81K
Average Volume (3M)115.77K
Market Cap
$86.45M
Enterprise Value$54.56M
Total Cash (Recent Filing)€43.47M
Total Debt (Recent Filing)€8.48M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Mar 26, 2025EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding37,103,779
10 Day Avg. Volume56,296
30 Day Avg. Volume115,768
Standard Deviation0.15
R-Squared0.02
Alpha-0.00188
Financial Highlights & Ratios
Price to Book (P/B)1.60
Price to Sales (P/S)4.06
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside415.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EDAP TMS News
PremiumCompany Announcements
EDAP TMS S.A. Reports Strong Q3 2024 Growth
PremiumCompany Announcements
EDAP TMS Sees Strong Growth and Advances in AI
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyData from a single-arm Phase 2 Study published indicated that 89.8% and 81.6% of patients reported reduction of acute pelvic pain at three and six months, respectively, following HIFU treatment.
Market AdoptionProcedure volume continues to grow, indicating continued adoption of HIFU among urologists.
Regulatory And Market ExpansionRecent approval of reimbursement in Switzerland strengthened company’s European and Middle Eastern commercial presence through the appointment of two new managers in Europe.
Bears Say
Clinical Study OutcomeInterim results showed the study did not achieve its primary goal of reducing acute pelvic pain in patients treated with HIFU compared to those given a Sham treatment.
Medical Research ResultsThe study with 60 participants did not successfully demonstrate a reduction in acute pelvic pain for those receiving HIFU treatment as opposed to Sham treatment.
Research And DevelopmentThe clinical trial involving 60 patients did not meet its main objective of alleviating acute pelvic pain in the HIFU treatment group compared to the Sham group.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EDAP FAQ
What was Edap Tms S.A.’s price range in the past 12 months?
Edap Tms S.A. lowest stock price was $2.27 and its highest was $8.50 in the past 12 months.
What is Edap Tms S.A.’s market cap?
Currently, no data Available
When is Edap Tms S.A.’s upcoming earnings report date?
Edap Tms S.A.’s upcoming earnings report date is Mar 26, 2025 which is in 119 days.
How were Edap Tms S.A.’s earnings last quarter?
Edap Tms S.A. released its earnings results on Nov 07, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.025.
Is Edap Tms S.A. overvalued?
According to Wall Street analysts Edap Tms S.A.’s price is currently Undervalued.
Does Edap Tms S.A. pay dividends?
Edap Tms S.A. does not currently pay dividends.
What is Edap Tms S.A.’s EPS estimate?
Edap Tms S.A.’s EPS estimate is -$0.11.
How many shares outstanding does Edap Tms S.A. have?
Edap Tms S.A. has 37,103,780 shares outstanding.
What happened to Edap Tms S.A.’s price movement after its last earnings report?
Edap Tms S.A. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went down -3.873%.
Which hedge fund is a major shareholder of Edap Tms S.A.?
Among the largest hedge funds holding Edap Tms S.A.’s share is Bruce & Co., Inc.. It holds Edap Tms S.A.’s shares valued at 1M.
---
EDAP TMS Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.89%
12-Months-Change
Fundamentals
Return on Equity
-35.41%
Trailing 12-Months
Asset Growth
-15.33%
Trailing 12-Months
Company Description
Edap Tms S.A.
EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
---
EDAP Earnings Call
Q3 2024
0:00 / 0:00
---
EDAP Stock 12 Month Forecast
Average Price Target
$12.00
▲(415.02% Upside)
Technical Analysis
Best Analysts Covering EDAP
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-28.01%
reiterated a buy rating 19 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -28.01% per trade.
---